FierceBiotech Names Constellation Pharmaceuticals as One of the “Fierce 15″ Biotech Companies of 2008

Constellation Pharmaceuticals is “Fierce,” on Leading Edge of Biotech

CAMBRIDGE, MA – June 24, 2008 – Constellation Pharmaceuticals announced today that it has been named to the annual FierceBiotech “Fierce 15” list, designating it as one of the top biotech companies of 2008. The editors of FierceBiotech evaluated hundreds of privately-held firms based on company vision, revenue potential, quality of deals, strength of technology, partnerships, and competitive market position. Constellation was determined to be one of the “fiercest,” proven by their creativity and innovations in the industry.

An internationally recognized daily newsletter reaching more than 65,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with a quick authoritative briefing on the day’s top stories, with a special focus on drug discovery and clinical trials.

“Constellation is a new player in a new field: epigenetics,” said John Carroll, Editor of FierceBiotech. “A new class of drugs that can regulate the epigenome can play a major role in gene expression, and that in turn can play a major role in controlling disease. With three of the top scientists in the field providing the brain trust, a solid lineup of leading venture investors supplying the money and a well-known biotech entrepreneur at the helm, Constellation is off to a solid start.”

Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the discovery and development of novel drugs targeting selective regulators of epigenetic function, In April, Constellation closed a $32 million Series A financing. Presently, the company is establishing its discovery platform and building a preclinical pipeline of epigenetic drugs.

“FierceBiotech is renowned for its advanced understanding of biotechnology companies and the industry as a whole,” said Mark Levin, Chief Executive Officer of Constellation. “Being selected as a member of the ‘Fierce 15’ is an honor that highlights Constellation’s potential to make a significant impact in the biotech market through leveraging epigenetics, the next biological breakthrough offering promise for targeting disease above and beyond the genome.”

The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. The complete list of ‘Fierce 15’ companies is available in today’s issue of FierceBiotech and on the FierceBiotech Web site at

About Constellation Pharmaceuticals

Constellation Pharmaceuticals is the first biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of Epigenetics, a new field of science which is focused on selective regulators of epigenetic function, which are critical to controlling gene function and expression. Constellation’s primary focus is in oncology, but the company’s platform will also be applicable to other therapeutics areas including autoimmune, inflammatory and neurological diseases. The Company’s founders represent the core thought leaders in Epigenetics, responsible for key advances, insights and discoveries in the field. Constellation Pharmaceuticals is located in Cambridge, Massachusetts. For more information, please visit the company’s website at

About FierceMarkets
FierceMarkets is a digital business media company serving vertical markets with email newsletters, web sites, and live events. Based in Washington, DC, FierceMarkets publications reach more than 450,000 executives in over 100 countries every business day. Current publications include The Business VoIP Report, FierceBioResearcher, FierceBiotech, FierceBroadbandWireless, FierceCIO, Fierce CIO: Tech Watch, FierceDeveloper, FierceFinance, FierceFinanceIT, FierceHealthCare http:///, FierceHealthFinance, FierceHealthIT, FierceIPTV, FierceMobileContent, FierceMobileIT, FierceOnlineVideo, FiercePharma, FierceSarbox, FierceTelecom, FierceVaccines, FierceVoIP, FierceWireless, and FierceWireless: Europe (

For Constellation:
Adriana Jenkins
Yates Public Relations

Heather Cox
FierceMarkets, Inc.
202-628-8778 x13